Big data adds clarity, certainty to clinical trial outcomes for AFib

The 33 million people with atrial fibrillation worldwide not only suffer from bothersome symptoms, but also face a fivefold increased risk of stroke and a twofold increased risk of death. Research teams led by Mayo Clinic published three connected studies on Friday, March 15, clarifying the benefits of catheter ablation versus rate- or rhythm-control medications to treat atrial fibrillation.

Two studies published in JAMA describe the results of the Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) clinical trial.

The third study, published in the European Heart Journal, displays how massive amounts of data collected from routine clinical practice can help transform care when put in the hands of researchers. This observational study, conducted in parallel to the CABANA trial, replicated the trial in a real-world patient population and compared the treatments in patients who would have been excluded from the trial.

The research team, led by Peter Noseworthy, M.D., a Mayo Clinic cardiologist, and Xiaoxi Yao, Ph.D., a health services researcher, used the OptumLabs Data Warehouse to examine the records of 183,760 patients with . These patients were treated with or medications alone between Aug. 1, 2009, and April 30, 2016, the enrollment period of the CABANA trial. The research team found that ablation was associated with a lower likelihood of patients experiencing one or more of the most serious outcomes: all-cause mortality, stroke, major bleeding and cardiac arrest, although the benefit associated with ablation was smaller in patients who would have been excluded from the trial.

"Our study was completed before the completion of the CABANA trial, with no knowledge of the trial findings," says Dr. Noseworthy. "This is unique, since most observational studies only replicate after the trials are published, which could introduce bias—consciously or unconsciously."

Big data research

"Clinical trials are the gold standard for evaluating treatment effects, but they have limitations such as strict eligibility criteria, small sample sizes, and cross over between treatment arms," notes Dr. Yao. "Using observational data, we hope to provide complementary evidence to help clinicians apply the findings to their everyday practice."

Using a cohort 84 times larger than the trial, this team found that most patients (73.8 percent) in routine practice would have been eligible for the CABANA trial. For these patients, ablation was associated with a 30 percent lower risk of stroke, death, major bleeding or cardiac arrest, compared to the risk when receiving medications alone. This result was similar to a CABANA secondary "per-protocol" analysis that excluded patients who deviated from their randomized treatment. (A per-protocol analysis examines only those participants who completed their assigned treatment.)

"Interestingly, in our study, we simulated the trial primary analysis by artificially creating crossover and found almost identical results as the trial: a 15 percent risk reduction in this study versus 14 percent in the trial," says Dr. Yao.

"Since the initial release of the CABANA trial findings last year, there have been questions in terms of how to interpret the primary trial result," she says. "However, using a much larger real-world population, the risk reduction was significant in our study even with crossover between treatment arms."

In this real-world cohort, 22.4 percent of patients met at least one CABANA exclusion criteria.

"These patients are often poor candidates for ablation, so the risk reduction with ablation that we found was smaller but still significant," says Dr. Noseworthy.

The remaining 3.8 percent of patients did not meet the trial inclusion criteria.

"These patients are those under 65 years old without any stroke risk factors," he says. "They could be good candidates for ablation for the purpose of symptom control, but their cardiovascular risk is very low."

The risk of serious events for patients receiving ablation also appeared to be 30 percent lower in this last group. However, because their overall risk is so small, the reduction was not statistically significant.

Implications for medical practice

The study provides valuable comparative effectiveness data for physicians as they seek to make evidence-based decisions for their patients regarding atrial fibrillation ablation.

"Our study results complement what we have seen in the CABANA trial itself and suggest that ablation may be associated with a lower risk of cardiovascular events than medical therapy alone," says Dr. Noseworthy. "However, the benefit may be smaller in patients who would have been excluded from the trial. Trial eligibility criteria could serve as a guide for selecting patients who may more likely benefit from ablation for cardiovascular risk reduction."

"This study also demonstrated that, when conducted rigorously, can have high internal validity, that is, producing results very similar to clinical ," Dr. Yao says. "These large real-world data not only help us interpret the controversial trial findings, but also provide additional evidence for who would have been excluded from the trial."

The research team included these Mayo Clinic experts Bernard Gersh, M.B., Ch.B., D.Phil., Douglas Packer, M.D., and Nilay Shah, Ph.D. The team also included David Kent, M.D., Tufts Medical Center, and Jonathan Piccini, M.D., Duke University Medical Center.

Explore further

Catheter ablation superior to standard drug therapy for heart failure

Provided by Mayo Clinic
Citation: Big data adds clarity, certainty to clinical trial outcomes for AFib (2019, March 15) retrieved 30 March 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments